These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Molecular basis of the anti-cancer effects of histone deacetylase inhibitors. Epping MT; Bernards R Int J Biochem Cell Biol; 2009 Jan; 41(1):16-20. PubMed ID: 18765293 [TBL] [Abstract][Full Text] [Related]
45. Histone deacetylase inhibitors as immunomodulators in cancer therapeutics. Shen L; Orillion A; Pili R Epigenomics; 2016 Mar; 8(3):415-28. PubMed ID: 26950532 [TBL] [Abstract][Full Text] [Related]
46. Targeted histone deacetylase inhibition for cancer therapy. Vigushin DM; Coombes RC Curr Cancer Drug Targets; 2004 Mar; 4(2):205-18. PubMed ID: 15032670 [TBL] [Abstract][Full Text] [Related]
47. Protein deacetylases: enzymes with functional diversity as novel therapeutic targets. Yoshida M; Shimazu T; Matsuyama A Prog Cell Cycle Res; 2003; 5():269-78. PubMed ID: 14593721 [TBL] [Abstract][Full Text] [Related]
50. Acetylation of proteins as novel target for antitumor therapy: review article. Di Gennaro E; Bruzzese F; Caraglia M; Abruzzese A; Budillon A Amino Acids; 2004 Jul; 26(4):435-41. PubMed ID: 15290351 [TBL] [Abstract][Full Text] [Related]
51. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Santini V; Gozzini A; Ferrari G Curr Drug Metab; 2007 May; 8(4):383-93. PubMed ID: 17504226 [TBL] [Abstract][Full Text] [Related]
52. Role of Histone Deacetylases (HDACs) in Epilepsy and Epileptogenesis. Citraro R; Leo A; Santoro M; D'agostino G; Constanti A; Russo E Curr Pharm Des; 2017; 23(37):5546-5562. PubMed ID: 29076408 [TBL] [Abstract][Full Text] [Related]
53. HDAC inhibitors for the treatment of cancer. Secrist JP; Zhou X; Richon VM Curr Opin Investig Drugs; 2003 Dec; 4(12):1422-7. PubMed ID: 14763127 [TBL] [Abstract][Full Text] [Related]
54. Histone acetylation and the cell-cycle in cancer. Wang C; Fu M; Mani S; Wadler S; Senderowicz AM; Pestell RG Front Biosci; 2001 Apr; 6():D610-29. PubMed ID: 11282573 [TBL] [Abstract][Full Text] [Related]
55. Development of histone deacetylase inhibitors for cancer treatment. Marchion D; Münster P Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177 [TBL] [Abstract][Full Text] [Related]
56. Development of an Efficient Screening System for HDAC Inhibitor Based on TCF Response Element. Pang C; Dai L; He G; Lu Y; Zhang B Anticancer Agents Med Chem; 2018; 18(15):2131-2136. PubMed ID: 30378504 [TBL] [Abstract][Full Text] [Related]
57. Histone deacetylase inhibitors in cancer therapy. Rosato RR; Grant S Cancer Biol Ther; 2003; 2(1):30-7. PubMed ID: 12673114 [TBL] [Abstract][Full Text] [Related]
58. The emerging role of histone deacetylases (HDACs) in UPR regulation. Kahali S; Sarcar B; Chinnaiyan P Methods Enzymol; 2011; 490():159-74. PubMed ID: 21266250 [TBL] [Abstract][Full Text] [Related]
59. Advances in targeting histone deacetylase for treatment of solid tumors. Shi MQ; Xu Y; Fu X; Pan DS; Lu XP; Xiao Y; Jiang YZ J Hematol Oncol; 2024 May; 17(1):37. PubMed ID: 38822399 [TBL] [Abstract][Full Text] [Related]